IMUX Immunic, Inc.

NASDAQ
$9.35

Immunic, Inc. (IMUX) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.82 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -34.3% since its last earnings release on August 11, 2026.

Immunic Beat Consensus Estimates
Tuesday, August 11, 2026 · 6:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 6:30 AM ET
Earnings Whisper
-
vs ($0.82)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $12.96

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immunic, Inc.

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.